Loading...
 
Translate Register Log In Login with facebookLogin and Register

Perimenopause symptoms (climacteric syndrome) substantially reduced by 4 weeks of Magnesium – Sept 2017

Impact of magnesium deficiency on the course of climacteric syndrome

Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (6): 118-26. (in Russian)
http://dx.doi.org/10.18565/aig.2017.6.118-26

VitaminDWiki and web


Makatsaria A.D., Dikke G.B.
1I.M. Sechenov First Moscow State Medical University, Moscow 119992, Malaya Trubetskaya str. 8 bld. 2, Russia
2Peoples’ Friendship University of Russia, Moscow 117198, Miklukho-Maklaya str. 8, Russia
Objective. To estimate the prevalence of magnesium deficiency (MD) and the characteristics of clinical symptoms in women with climacteric syndrome (CS) and to determine the efficacy of Magne B6 forte in improving the quality of life in patients.

Subjects and methods. A total of 3808 women with climacteric syndrome were examined. In the first phase of the study, the symptoms of CS and the prevalence of MD were assessed using the standardized Mood Disorder Questionnaire (MDQ) and/or serum magnesium levels were measured. The quality of life in the women with CS was estimated according to the WHOQOL-BREF questionnaire. In the second step, the patients with MD were treated with a magnesium citrate-containing drug for 4 weeks; the therapeutic efficiency was evaluated.

Results. The high prevalence of MD was noted in the patients with CS (60%). The clinical efficacy of Magne B,6 forte was confirmed by an

  • increase in serum magnesium levels (from 0.67±0.09 to 0.80±0.25 mmol/l; p < 0.001),
  • normalization of MDQ scores (from 43.4±11.9 to 24.0±14.9; p < 0.001),
  • a reduction in the severity of more than half of the CS symptoms by 2-2.5 times and
  • an improvement in quality of life.

Conclusion. The use of Magne B6 forte in patients with CS contributes to improvements in the course of the disease and in the quality of life.

References

  • 1. Gromova O.A., Serov V.N., Torshin I.Yu. Magnesium in obstetrics and gynecology: history of application and modern views. Trudny patsient. 2008; 8 (6): 20-8. (in Russian)
  • 2. Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16 000 individuals. Magnes. Res. 2001; 14(4): 283-90.
  • 3. Serov V.N., Baranov I.I., Blinov D.V., Zimovina U.V., Sandakova E.A., Ushakova T.I. Results of investigation of magnesium deficiency in patients with hormone-dependent diseases. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2015; 6: 91-7. (in Russian)
  • 4. Jurczak A., Brodowski J., Grochans E. et al. Effect of menopausal hormone therapy on the levels of magnesium, zinc, lead and cadmium in post-menopausal women. Ann. Agric. Environ. Med. 2013; 20(1): 147-51.
  • 5. Muneyyirci-Delale O., Nacharaju V.L., Dalloul M., Altura B.M., Altura B.T. Serum ionized magnesium and calcium in women after menopause: inverse relation of estrogen with ionized magnesium. Fertil. Steril. 1999; 71(5): 869-72.
  • 6. Stanton M.F., Lowenstein F.W. Serum magnesium in women during pregnancy, while taking contraceptives, and after menopause. J. Am. Coll. Nutr. 1987; 6(4): 313-9.
  • 7. Gromova O.A., Limanova O.A. Magnesium deficiency and muscle cramps in pregnant women: the possibility of therapy (clinico-pharmacological lecture). Ginekologiya. 2014; 16 (2): 70-7. (in Russian)
  • 8. The World Health Organization Quality of Life (WHOQOL)-BREF. © World Health Organization; 2004. Available at: http://www.who.int/
  • 9. Spasov A.A. Magnesium in medical practice. Volgograd; 2000. 272p. (in Russian)
  • 10. Budanov P.V. Treatment of premenstrual syndrome: modern concepts and perspectives. Trudny patsient. 2012; 10(2-3): 34-7. (in Russian)
  • 11. Nedogoda S.V. The role of magnesium preparations in the management of patients with a therapeutic profile. Lechaschiy vrach. 2009; 6: 16-9. (in Russian)
  • 12. Mubarakshina O.A. Features of the use of magnesium preparations by pregnant women. Farmateka. 2013; 18: 2-5. (in Russian)
  • 13. Torshin I.Yu., Gromova O.A. Mechanisms of antistress and antidepressant action of magnesium and pyridoxine. S.S. Korsakov Journal of Neurology and Psychiatry. 2009; 109(11): 107-11. (in Russian)
  • 14. Chekman I.S., Gorchakova N.A., Nikolay S.L. Magnesium in medicine. Kishinev; 1992. 101p. (in Russian)
  • 15. Gunther T. The biochemical function of Mg 2+ in insulin secretion, insulin signal transduction and insulin resistance. Magnes. Res. 2010; 23(1): 5-18.
  • 16. Torshin I.Yu., Gromova O.A. Connective tissue dysplasia, cell biology and molecular mechanisms of magnesium exposure. Breast cancer. 2008; 16(4): 230-8. (in Russian)
  • 17. Serov V.N., Blinov D.V., Zimovina U.V., Dzhobava E.M. Results of an investigation of the prevalence of magnesium deficiency in pregnant women. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2014; 6: 33-40. (in Russian)
  • 18. López-González B., Molina-López J., Florea D.I. еt al. Association between magnesium-deficient status and anthropometric and clinical-nutritional parameters in posmenopausal women. Nutr. Hosp. 2014; 29(3): 658-64.
  • 19. Gromova OA, Torshin I.Yu., Grishina Т.R. World experience in the use of magnesium citrate in medicine. Trudny patsient. 2010; 8(8): 35-44. (in Russian)
  • 20. Martin V.T., Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis. Headache. 2006; 46:365-86.
  • 21. Park H., Parker G.L., Boardman C.H. et al. A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Support Care Cancer. 2011; 19(6): 859-63.
  • 22. Herrada J., Gupta A., Campos-Gines A.F. et al. Oral magnesium oxide for treatment of hot flashes in women undergoing treatment for breast cancer: A pilot study. Chicago: 2010 ASCO Annual Meeting; 2010.
  • 23. Abbasi B., Kimiagar M., Sadeghniiat K. et al. The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial. J. Res. Med. Sci. 2012; 17(12): 1161-9.
  • 24. Stanisławska M., Szkup-Jabłońska M., Jurczak A. et al. The severity of depressive symptoms vs. serum Mg and Zn levels in postmenopausal women. Biol. Trace Elem. Res. 2014; 157(1): 30-5.
  • 25. Derom M.L., Sayón-Orea C., Martínez-Ortega J.M., Martínez-González M.A. Magnesium and depression: a systematic review. Nutr. Neurosci. 2012;16: 191-206.
  • 26. Jurczak A., Brodowski J., Grochans E. et al. Effect of menopausal hormone therapy on the levels of magnesium, zinc, lead and cadmium in post-menopausal women. Ann. Agric. Environ. Med. 2013; 20(1): 147-51.

Created by admin. Last Modification: Thursday August 3, 2017 12:42:58 GMT-0000 by admin. (Version 4)
See any problem with this page? Report it (FINALLY WORKS)